Cite

HARVARD Citation

    Driessen, M. et al. (2018). Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory medicine. pp. 130-137. [Online]. 
  
Back to record